DEXAMETHASONE SUSTAINED DRUG DELIVERY IMPLANT FOR THE TREATMENT OF SEVERE UVEITIS

Abstract

From the Departments of Ophthalmology, *Duke University, Durham, North Carolina, †University of Kentucky, Lexington, and ‡Tufts New England Medical Center, Boston, Massachusetts. Supported by NIH Grant EY09106 (Dr. Jaffe), the Adler Foundation (Dr. Jaffe), and Research to Prevent Blindness, Inc. Dr. Jaffe is a Lew R. Wasserman Merit Award Recipient. Drs. Pearson and Ashton have applied for a patent on the dexamethasone sustained drug delivery device and, as such, may have a financial interest in it. Correspondence: Glenn J. Jaffe, MD, Duke University Eye Center, Duke University, Box 3802, Durham, NC 27710; e-mail: [email protected] RETINA,TMThe Journal of Retinal and Vitreous Diseases, encourages authors to submit Brief Reports describing unusual findings, new techniques, and new instruments. Material submitted for consideration in this section of the journal is done so with the assumption that the data provided do not duplicate previously published material and that the material has not been submitted for consideration elsewhere. Each author must sign a disclosure to this effect (see Instructions to Authors for complete wording of transfer letter). Brief Reports submitted for this section of the journal may be subjected to the standard review process that is applied to other material submitted to RETINA. Brief Reports should follow the requirements listed in the Instructions to Authors, with the following caveats: Brief Reports should not exceed 4 pages in length; no more than 5 references should be cited; and each Brief Report should include no more than 4 figures.